Firas B Badin, MD

Hematology Oncology
Gender: Male
4.9 of 5 (222 Ratings)
Accepting New Patients

Clinical Focus

Cancerous tumors, Lung Cancer

Practice Locations

Education

Fellowship

University of Kentucky Medical Center

Internship

Newark Beth Israel Medical Center

Residency

Newark Beth Israel Medical Center

Medical School

University of Damascus School of Medicine

Board Certifications

-

American Board of Internal Medicine

-

American Board of Internal Medicine

Hospital Affiliations

  • Baptist Health Medical Group
  • Baptist Health Lexington
  • Baptist Health Richmond

Philosophy of Care

Baptist Health Medical Group is a comprehensive, multispecialty network of physicians and advanced practice clinicians. Our providers are committed to providing compassionate, patient-centered care and strive to treat our patients the way we would want to be treated, every time, at every Baptist Health location.

Reviews

Patient Experience Ratings

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Overall Rating
4.9 out of 5 (222 Ratings)
Review Categories
Patient Comments

Research

  • Breast Cancer

    EA1181: Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer)

    Trial Details
  • Extensive-stage Small-cell Lung Cancer

    EMERGE 402: Stage IV observational study for adult patients with metastatic SCLC

    Trial Details
  • Lung Cancer

    A081801-Alchemist Sub-Study: This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery.

    Trial Details
  • Lung Cancer

    Alliance A151216: ALCHEMIST - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

    Trial Details
  • Non-small Cell Lung Cancer

    EF-36/Keynote: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

    Trial Details
  • Non-small Cell Lung Cancer (NSCLC)

    Pacific 9: A Phase III, double-blind, placebo-controlled, Randomized, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

    Trial Details
  • Non-small Cell Lung Cancer (NSCLC)

    BeiGene A317-A1217-302: A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, or Metastatic Non-Small Cell Lung Cancer

    Trial Details
  • Non-small Cell Lung Cancer (NSCLC) (WIRB-22-0106)

    Skyscraper: A Phase II/III, Randomized, Double Blind, Placebo-Controlled Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab

    Trial Details
  • NSC Lung Cancer

    Razor-Encore - A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay

    Trial Details
  • Previously Treated Non-Small Cell Lung Cancer

    LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

    Trial Details
  • Small Cell Lung Carcinoma

    MK3475-B98: A Phase 1b/2 Study to Evaluate Efficacy and Safety of Pembrolizumab in Combination w Investigational Agents for Treatment of Participants With PD-1/L1- refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (Keynote-B

    Trial Details

About Firas B Badin

View Hide Transcript
♪ [music]

♪ - [Susan]

I've been a nurse for 30 plus years, and also I've been the CEO of a hospital in Irvine, Kentucky, and I've always been actively involved in healthcare and treating patients and being with patients. I walked, you know, all the time. I exercised on a routine basis. I tried to eat right and reduce any type of risk factors involved with cancer.

♪ [music]

♪ I knew that I had to do something because I knew that women have a tendency to ignore their signs and symptoms, and they have a tendency to not make themselves a priority. ♪ [music]

♪ So I was diagnosed with lung cancer. It was a early stage of lung cancer. You know, as a nurse and having a healthcare background doesn't make it any easier when you have the diagnosis of cancer, especially when you first face it, but I think that when I entered into the system and started being cared for by Dr. Badin, I mean, he provided me with that care that reduced my anxiety.

- [Dr. Badin]

Cancer diagnosis is really a life-changing event. It takes really a strong person, a true hero to face cancer. I remember meeting Susie when she was first diagnosed with cancer, and she was looking for something beyond the standard of care. You know she can get surgery anywhere.

She can get chemotherapy anywhere, but knowing that at Baptist Richmond, we can not only do that, but also we can give her a new research, a new clinical trial that give her further hope and potentially better results. She was very excited.

- As a nurse, if I can do something to help other people in the future, that's what I want to do. They made it easy for me. I mean, they're wonderful people, all so very kind and caring nurses that helped me for the research.

- We cannot provide top-notch, world-class care to cancer patients without having full access to research as well as clinical trials. With research, what we try to do is we try to bring the future to today.

- One of my favorite things to do is to work out with my trainer, with my friend, and even during my treatment, I was able to continue to do exercise and to do fitness, and I think that was important.

- Getting the treatment that you need closer to home is always better. It's much easier to be with your family, be with your friends, with your own environment, and that's what we do here at Baptist Richmond, again, trying to be local, be close to patients, and bring everything that we offer at bigger centers, have it available at this place right here in Richmond.

- It's good to know that you have a physician who is involved in the research component of it, and I know that Dr. Badin was a leader.

- I am very proud to be in Baptist family. I'm happy to call this is home for me for the last 10 years. I'm proud to work for them because I love their mission. It's always been patient-focused.

I love being the director of research. I love being involved in research, and I don't see this changing anytime soon.

- When I look back on that whole experience, although it was difficult, it was scary and frightening and challenging, I'm also very grateful for the outcome that I have. I'm grateful that I'm healthy in my retirement age, and I am able to do the things that I enjoy. It's a blessing to be able to have such a great story to tell. ♪ [music]

Susan's Cancer Patient Story